Uncategorized
EyeGate reports $3.3 million loss in second quarter
EyeGate Pharmaceuticals reported a net loss of $3.3 million in the second quarter of 2017 compared with a net loss of $3.8 million in 2016’s second quarter, according to a press release.Research and development costs decreased from $2.5 million to $2.3 million due to reduced activity in the company’s phase 3 anterior uveitis treatment trial.